| Title |
New treatments for myasthenia: a focus on antisense oligonucleotides
|
|---|---|
| Published in |
Drug Design, Development and Therapy, January 2013
|
| DOI | 10.2147/dddt.s25716 |
| Pubmed ID | |
| Authors |
Corrado Angelini, Sara Martignago, Michela Bisciglia |
| Abstract |
Autoimmune myasthenia gravis (MG) is a neuromuscular disorder caused by autoantibodies directed against the acetylcholine receptor (AChR). Current symptomatic therapy is based on acetylcholinesterase (AChE) drugs. The available long-term current therapy includes steroids and other immunomodulatory agents. MG is associated with the production of a soluble, rare isoform of AChE, also referred as the "read-through" transcript (AChE-R). Monarsen (EN101) is a synthetic antisense compound directed against the AChE gene. Monarsen was administered in 16 patients with MG and 14 patients achieved a clinically significant response. The drug is now in a Phase II study. Further investigations are required to confirm its long-term effects. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | 3% |
| Canada | 1 | 3% |
| Iran, Islamic Republic of | 1 | 3% |
| Japan | 1 | 3% |
| United States | 1 | 3% |
| Unknown | 30 | 86% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 7 | 20% |
| Student > Postgraduate | 5 | 14% |
| Other | 4 | 11% |
| Researcher | 4 | 11% |
| Student > Master | 4 | 11% |
| Other | 8 | 23% |
| Unknown | 3 | 9% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 37% |
| Neuroscience | 5 | 14% |
| Agricultural and Biological Sciences | 4 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 9% |
| Biochemistry, Genetics and Molecular Biology | 2 | 6% |
| Other | 2 | 6% |
| Unknown | 6 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 April 2014.
All research outputs
#15,879,822
of 25,584,565 outputs
Outputs from Drug Design, Development and Therapy
#876
of 2,254 outputs
Outputs of similar age
#178,462
of 289,948 outputs
Outputs of similar age from Drug Design, Development and Therapy
#8
of 16 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 36th percentile – i.e., 36% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,254 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has gotten more attention than average, scoring higher than 59% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 289,948 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.